Aaron Wealth Advisors LLC Grows Stock Position in Astrazeneca Plc $AZN

Aaron Wealth Advisors LLC raised its stake in shares of Astrazeneca Plc (NYSE:AZN) by 31.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 27,984 shares of the company’s stock after buying an additional 6,769 shares during the period. Aaron Wealth Advisors LLC’s holdings in Astrazeneca were worth $2,573,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Triumph Capital Management purchased a new position in shares of Astrazeneca during the 3rd quarter valued at about $25,000. Bangor Savings Bank raised its stake in shares of Astrazeneca by 102.7% during the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after buying an additional 154 shares during the last quarter. Rakuten Investment Management Inc. purchased a new position in shares of Astrazeneca during the 3rd quarter valued at about $31,000. YANKCOM Partnership acquired a new stake in shares of Astrazeneca during the 4th quarter valued at about $31,000. Finally, JPL Wealth Management LLC acquired a new stake in shares of Astrazeneca during the 3rd quarter valued at about $35,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Astrazeneca Trading Down 0.3%

AZN stock opened at $202.85 on Tuesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.72 and a current ratio of 0.94. Astrazeneca Plc has a 12-month low of $122.48 and a 12-month high of $212.71. The stock has a market capitalization of $314.60 billion, a P/E ratio of 30.97, a PEG ratio of 1.53 and a beta of 0.35.

Astrazeneca Dividend Announcement

The company also recently disclosed a dividend, which was paid on Monday, March 23rd. Investors of record on Friday, February 20th were issued a $1.595 dividend. This represents a yield of 156.0%. The ex-dividend date was Friday, February 20th. Astrazeneca’s payout ratio is presently 66.26%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on AZN shares. Weiss Ratings started coverage on Astrazeneca in a research report on Wednesday, March 11th. They set a “buy (b)” rating on the stock. TD Cowen restated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. HSBC restated a “buy” rating and set a $108.00 target price on shares of Astrazeneca in a research report on Wednesday, December 10th. Citigroup started coverage on Astrazeneca in a research report on Tuesday, January 27th. They set a “buy” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Astrazeneca in a research report on Friday, February 6th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Astrazeneca currently has an average rating of “Moderate Buy” and an average target price of $95.75.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.